Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06396780
Other study ID # 039A01
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 30, 2024
Est. completion date March 31, 2025

Study information

Verified date April 2024
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to describe the current status of treatment adherence in children with Helicobacter pylori infection, understand the medication literacy, medication beliefs of the children, knowledge of H. pylori among caregivers, medication beliefs, medication support, and explore the influencing factors of medication adherence.


Description:

Helicobacter pylori infection usually occurs in childhood and persists into adulthood, and is closely related to the occurrence of chronic gastritis, peptic ulcer, and gastric cancer. However, in recent years, the eradication success rate of Helicobacter pylori infection has gradually decreased, while the drug resistance rate has gradually increased, and it is urgent to improve the success rate of first eradication in children. Medication compliance is closely related to drug resistance, so it is necessary to investigate medication compliance and its influencing factors during Helicobacter pylori eradication in children.Children and caregivers who meet the inclusion and exclusion criteria were invited to individually complete questionnaire surveys. Part One: Children infected with Helicobacter pylori and undergoing treatment were invited to complete the questionnaire surveys independently. The children completed the Medication Literacy Questionnaire, Medication Beliefs Specific Questionnaire, and Medication Adherence Questionnaire. Part Two: Caregivers of the children completed the survey questionnaires, including a demographic information form, H. pylori knowledge questionnaire, Medication Beliefs Specific Questionnaire, and Medication Support Questionnaire.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 233
Est. completion date March 31, 2025
Est. primary completion date February 28, 2025
Accepts healthy volunteers No
Gender All
Age group 8 Years to 18 Years
Eligibility Children Inclusion Criteria: - 1.Children aged 8-18 years old - 2. whose diagnosis meets the diagnostic criteria for Helicobacter pylori infection in the Expert Consensus on Diagnosis and Treatment of Helicobacter Pylori Infection in Chinese Children (2022) - 3. Children who receive Helicobacter pylori eradication therapy Children Exclusion Criteria: - 1.Children are diagnosed with other chronic conditions and take other medications for a long time - 2.Unable to communicate with readers in Chinese normally Caregiver Inclusion Criteria: - 1.Caregivers of children who meet the diagnostic criteria for Helicobacter pylori infection in the Expert Consensus on Diagnosis and Treatment of Helicobacter pylori Infection in Children in China (2022) - 2.Able to communicate normally Caregiver Exclusion Criteria: - 1.Not living with children - 2.Not familiar with the use of children

Study Design


Locations

Country Name City State
China Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Status of adherence Using the Medication Adherence Questionnaire to assess the level of medication adherence in pediatric patients. The questionnaire primarily includes four aspects: adherence to timing, dosage, frequency, and persistence in taking medication. Each aspect consists of four options: (1) Impossible to do; (2) Occasionally possible to do; (3) Basically possible to do; (4) Completely possible to do. Using a scoring method, each option is assigned a score of 1, 2, 3, or 4, respectively, with a score range of 4 to 16 points. Complete adherence is scored as 16 points, basic adherence as 13 to 15 points, minimal adherence as 5 to 12 points, and difficulty as 4 points. baseline
Secondary Medication literacy Medication literacy questionnaire was used to investigate the drug literacy level of children. The questionnaire consisted of 9 items, covering the drug name, dosage and adverse reactions of discharged patients. The 2-point system was used to score points (1 for correct answers and 0 for wrong answers), and the total score of the items was 9 points. Those who scored 0-2 points were considered to have poor drug literacy level, those who scored 3-5 points were considered to have medium drug literacy level, and those who scored 6-7 points were considered to have excellent drug literacy level. Baseline
Secondary Beliefs about medicine The Medication Beliefs Specific Questionnaire is used to assess the medication belief levels of pediatric patients and their caregivers. The questionnaire comprises two dimensions: medication necessity and medication concerns, totaling 10 items. Responses are rated on a 5-point Likert scale. Scores for medication necessity and medication concerns dimensions range from 5 to 25 points. Medication belief is calculated as the difference between scores for medication necessity and medication concerns (-20 to 20). Belief levels are categorized as low if the total score is less than 0, moderate if the total score is 0, and high if the total score is greater than 0. Baseline
Secondary Medication support The Medication Support Questionnaire assesses caregiver medication support behaviors. The questionnaire consists of 6 items, with each item offering 4 options: ? Impossible to do; ? Occasionally possible to do; ? Basically possible to do; ? Completely possible to do. Using a scoring method, each option is assigned a score of 1 to 4 points sequentially. The score range is from 6 to 24 points, with higher scores indicating better caregiver medication support. A score greater than 21 points indicates good caregiver medication support, while a score of 20 or less indicates poor caregiver medication support. Baseline
Secondary Helicobacter pylori knowledge Using the Helicobacter pylori Knowledge Questionnaire to investigate the caregivers' level of knowledge about Helicobacter pylori. Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05061732 - Helicobacter Pylori Eradication and Follow-up Phase 4
Completed NCT03779074 - Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies Phase 3
Completed NCT06076681 - A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules Phase 1/Phase 2
Recruiting NCT05329636 - Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy Phase 1/Phase 2
Recruiting NCT05065138 - Comparison of Helicobacter Pylori Eradication Effect Before and After Training of Gastroenterologists N/A
Completed NCT05049902 - Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication Phase 4
Not yet recruiting NCT06200779 - Tailored vs. Empirical Helicobacter Pylori Infection Treatment Phase 4
Not yet recruiting NCT06037122 - Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication
Completed NCT04617613 - Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait Phase 4
Completed NCT02873247 - Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori
Withdrawn NCT02552641 - Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Phase 4
Completed NCT02557932 - Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication Phase 3
Recruiting NCT02249546 - Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Phase 4
Completed NCT01933659 - Anti-H. Pylori Effect of Deep See Water Phase 3
Unknown status NCT01464060 - 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Phase 4
Completed NCT00841490 - Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults N/A
Recruiting NCT05549115 - Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection N/A
Recruiting NCT05728424 - One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL Phase 3
Recruiting NCT05997433 - Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori(SHARE2302) N/A
Completed NCT04708405 - The Relationship Between Helicobacter Pylori Infection and Inflammatory Bowel Diseases: A Real-life Observation